Concepedia

Occupational and ambient radiation exposures from Lu-177 DOTATATE during targeted therapy

Abdelmoneim Sulieman, Fareed H. Mayhoub, Hassan Salah, Huda I. Almohammed, M. Alkhorayef, Belal Moftah, M. Al Rowaily, D.A. Bradley

Applied Radiation and Isotopes · 2020 · 19 citations · 15 references

DOI

Concepts

References

15

Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

, , +17

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

John J. Zaknun, Lisa Bodei, Jan Mueller‐Brand et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 809 citations · Full text

, , +17

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

Lisa Bodei, Marta Cremonesi, Mahila Ferrari et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2008 · 424 citations

, , +17

Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing <sup>177</sup>Lu-DOTA-Octreotate Treatment

Mattias Sandström, Ulrike Garske‐Román, Silvia Johansson et al. · Journal of Nuclear Medicine · 2012 · 287 citations · Full text

, , +17

Dosimetry in Peptide radionuclide receptor therapy: a review.

Marta Cremonesi, Mahila Ferrari, Lisa Bodei et al. · PubMed · 2006 · 206 citations

, , +17